Keeping you up to date on recent developments in cardiology, including: COVID-19 an independent risk factor for acute ischemic stroke; New heart valve holds hope for open heart surgery; Company unveils results on therapy to treat cardiovalvular diseases.
Keeping you up to date on recent developments in neurology, including: A focused approach to imaging neural activity in the brain; International study discovers 3 potential new targets for treating epilepsy; New genetic mutations linked to ASD; Alzheimer’s study finds higher risk of disease in women vs. men due to hormones.
Keeping you up to date on recent developments in diagnostics, including: Border detection algorithm for melanoma; Predicting future suicide risk; Multiracial study gives new diabetes insights; Patient genetic variants linked to wound microbiomes.
Keeping you up to date on recent developments in orthopedics, including: Nuclear softening allows cells to move into dense tissue, encouraging injury repair; 3D X-ray reveals secrets from inside bones; Fantastic muscle proteins and where to find them.
Keeping you up to date on recent developments in oncology, including: Focused ultrasound may help thwart glioblastoma; Manipulating the macrophage for cancer therapy; FDA’s oncology center initiates patient voice program; FDA’s oncology center initiates patient voice program; Sedentary behavior predictive of cancer mortality.
By targeting chimeric antigen receptors (CARs) to a senescence marker, researchers at Memorial Sloan-Kettering Cancer Center have developed a CAR T cell that had beneficial effects in mouse models of both liver fibrosis and lung cancer.
Keeping you up to date on recent developments in neurology, including: High-resolution 3D model reveals similarity in Alzheimer's, diabetes; New MRI test shows promise in detecting CTE in football players; Neuropointdx reports metabolic biomarker found in children with ASD.
On June 17, the FDA approved checkpoint blocker Keytruda (pembrolizumab, Merck & Co. Inc.) “for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [?10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.”
Keeping you up to date on recent developments in diagnostics, including: Improving diagnosis of pulmonary hypertension; A web-based COVID-19 assessment tool; Discovering pharmacological enzyme activators.